ESMO 2021
The European Society For Medical Oncology Congress 2021
September 16-21, 2021 | Virtual
Nivolumab plus ipilimumab as a standard of care for unresectable MPM: 3-year CheckMate 743 update
ESMO-MCBS - A well-validated tool to assess clinical benefits of novel anti-cancer treatments in real-world practice
Population risk stratification in the early detection and personalized treatment for breast cancer
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent or metastatic cervical cancer: Phase 3 KEYNOTE-826 study
Durvalumab plus EP shows sustained OS benefit in ES-SCLC: 3-year update from phase 3 CASPIAN study